Roche Holding Ltd - Oct 28, 2021 Form 3 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role
10%+ Owner
Signature
/s/ Jared Cohen, as Attorney-in-fact
Stock symbol
TRDA
Transactions as of
Oct 28, 2021
Transactions value $
$0
Form type
3
Date filed
10/28/2021, 09:04 PM
Previous filing
Oct 4, 2021
Next filing
Nov 4, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TRDA Series A Preferred Stock Oct 28, 2021 Common Stock 2.5M See Footnote F1, F2
holding TRDA Series B Preferred Stock Oct 28, 2021 Common Stock 318K See Footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A Preferred Stock is convertible into common stock on a 1-for-7.235890014 basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock is convertible into Common Stock on a 1-for-7.235890014 basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.
F2 Represents shares held by Roche Finance Ltd ("Roche Finance"). Roche Finance is a wholly owned subsidiary of Roche Holding Ltd ("Roche Holding"), a Swiss corporation whose shares are traded on the SIX Swiss Exchange. Roche Holding is the indirect beneficial owner of these securities of the Issuer. This Form 3 shall not be deemed an admission that any reporting person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 3.

Remarks:

Exhibit 24 - Power of Attorney